Surging Geriatric Population Supporting the Age-Related Macular Degeneration Sector Growth

ALAMO, Calif. - Aug. 8, 2019 - PRLog -- The information and data in the publication "Global Age-related Macular Degeneration Market (http://bit.ly/2ZFc39y) Size, Share, Development, Growth and Demand Forecast to 2022" represent the research and analysis of data from various primary and secondary sources. The bottom-top approach has been used to calculate the global market size by type. P&S Intelligence analysts and consultants interacted with authorities from leading companies of the concerned domain, to substantiate every value of data presented in the report. The company bases its primary research on discussions with prominent professionals and analysts in the industry, which is followed by informed and detailed, online, and offline research.

Smoking, obesity, high blood pressure, high cholesterol, poor diet, ultra-violet radiation, hereditary, and light eye color are some of the risk factors associated with AMD. In early stages, macular degeneration may not have symptoms, although with the progress of the disease it may have symptoms such as deterioration in central vision or dark spot, and blurriness.

Factors such as stringent regulatory requirements and increase in off label use are inhibiting the growth of the global market. The increasing awareness of AMD is the key trend observed in the global age-related macular degeneration market.

Some of the key companies operating in the global age-related macular degeneration market (https://www.psmarketresearch.com/market-analysis/age-rela...) include Novartis AG, F. Hoffmann-La Roche Ltd., Bayer AG, Regeneron Pharmaceutical, Inc., Acucela, Ophthotech Corporation, Neurotech Pharmaceuticals, Inc., GlaxoSmithKline plc, StemCells Inc and Alimera Sciences, Inc.